secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001193125-23-046525
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Novartis terminates collaboration with Pliant; discontinues NASH program PLN-1474
--------------------------------------------------------------------------------

- Novartis notified Pliant on Feb 17, 2023 of termination of Collaboration and License Agreement, effective April 18, 2023.
- Novartis is divesting clinical NASH assets and discontinuing development of PLN-1474 (integrin αvβ1 inhibitor for liver fibrosis).
- Pliant had received $50M upfront and $29M in contingent payments; up to $416M in future milestones and royalties now terminated.
- All rights and licenses, including PLN-1474 and validated research target compounds, revert to Pliant.
- Research term for up to three additional integrin targets concludes Q1 2023; one target validated with multiple development candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312523046525/0001193125-23-046525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312523046525/d463670d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-046525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer